

Preliminary Report

Month, date, year

**Centers for Disease Control and Prevention (CDC)**  
***Mycobacterium tuberculosis* and non-tuberculous mycobacteria**  
**Drug Susceptibility Testing Performance Evaluation Program**

Subject: Preliminary Report for Panel Shipment Year-XX

Dear Participant:

Attached you will find the preliminary susceptibility testing results for the cultures of *M. tuberculosis* sent to you in Month year. These preliminary results were determined by the candidate reference laboratories and may not represent the consensus of all participants. Although the Centers for Disease Control and Prevention (CDC) recommends the radiometric method for routine *M. tuberculosis* drug susceptibility testing, this preliminary report provides the results used in the conventional (agar proportion) method except in the case of pyrazinamide. Participants should use the equivalent radiometric concentrations to determine their results.

The participant test results for the NTM culture will be provided in the detailed aggregate report of susceptibility results and methods.

This preliminary report will provide you with timely information about the cultures sent to your laboratory. A detailed aggregate report of susceptibility testing results and methods reported by all participants for this panel of four (4) *M. tuberculosis* isolates and (1) NTM, if applicable, will be emailed before the next scheduled shipment. For additional information or to comment on this report, you may Angela Ragin at 1-888-465-6062 or [aragin@cdc.gov](mailto:aragin@cdc.gov) or Sandra Neal at 404 498-2238.

We appreciate your support and participation in the *M. tuberculosis* and NTM Drug Susceptibility Testing Performance Evaluation Program.

Sincerely yours,



Angela Ragin, PhD  
Project Coordinator  
NCPDCID/DLS Mailstop G-23,  
Centers for Disease Control and Prevention  
Ph: 404 498-2241 Fx: 404 498-2215  
email: [aragin@cdc.gov](mailto:aragin@cdc.gov)



Sandra W. Neal, B.S., MT(ASCP), M.S., P.M.P.  
Project Manager  
NCPDCID/DLS Mailstop G-23,  
Centers for Disease Control and Prevention  
Ph: 404 498-2238 Fx: 404 498-2215  
email: [sneal@cdc.gov](mailto:sneal@cdc.gov)

**Preliminary Report**

**Susceptibility Testing Results:  
*M. tuberculosis* Isolates  
Panel Shipment 2009-XX**

<b>STRAIN</b>	<b>DRUG RESISTANCE</b>
K	Isoniazid at 0.2 µg/ml
L	Fully Susceptible
M	Pyrazinamide at 100 µg/ml
N	Streptomycin at 10 µg/ml